본문바로가기

ABOUT US

Drugging the undruggable targets

  • ABOUT US
VISION
Discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs
MISSION
Drugging the undruggable targets with small molecules and new chemical modalities
Cyrus Therapeutics is a leading biotechnology company that is discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs. It is estimated that about 3,000 targets are ‘undruggable’ (about 16% of a total of 20,000 human proteins). We are committed to making our mission—‘drugging the undruggable targets’—possible with small molecule drugs as well as new chemical modalities such as targeted protein degraders.

LEADERSHIP

OUR PARTNERS

To make our drug discovery faster and more effective, we are collaborating with top-tier drug discovery companies, research institutes, and universities including Bridge Biotherapeutics, HK Inno.N, HYUNDAI PHARM, Kanaph Therapeutics, the Korean Research Institute of Chemical Technology (KRICT), MOGAM Institute for Biomedical Research (MIBR) and YONSEI CANCER CENTER.
Ph.D. / CEO, Founder
Byong-Moon Kim
  • Executive Senior Vice President, Head of R&D/Global Business, CJ HealthCare
  • Executive Senior Vice President, Head of Biomed Strategy Division, CJ CheilJedang
  • Senior Vice President, Head of The Research Institute, Dong-A ST/Dong-A Socio Holdings
  • Director, Board of Directors, Institute Pasteur Korea
  • Visiting Scientist, The Catholic University of America in Washington, D.C., USA
  • Visiting Scientist, NIAAA, National Institutes of Health in Maryland, USA
  • B.S./M.S./Ph.D. in Biotechnology, Korea University
RPh / CBO
Seong Jin KIM
  • CBO, CJ HealthCare Inc.
  • CBO, CJ CheilJedang Inc.
  • Head of Development, TaeJoon Pharm
  • Team leader, LG LifeSciences(BD, RA, Clinical, Strategic Planning)
  • B.S. in Pharmacy, Chungang University
Ph.D. / CSO
Wooseok Han
  • Principal Scientist, Novartis Institutes for BioMedical Research
  • Scientist, Chiron Corporation
  • Post-doc. Fellow, The Scripps Research Institute
  • Ph.D. in Organic Chemistry, University of Toronto
  • M.S. in Organic Chemistry, KAIST
  • B.S. in Chemistry, Yonsei University
Ph.D. / Head of CMC
Seogbeom Song
  • Head of New drug development center, CJ Healthcare
  • Head of Drug Analysis Center, CJ Healthcare
  • Ph.D. in Chemistry, KAIST
  • B.S./M.S. in Chemistry, Korea University
Ph.D. / Head of Translational Research
Myoungki Baek
  • Head of Drug Discovery Center, Hyundai Pharm.
  • Translational Research Team Leader, SK Biopharmaceuticals.
  • Pharmaceutical R&D Group Leader, CJ Cheiljedang
  • Ph.D. in Biopharmaceutics, Martin Luther University Halle Wittenberg
  • M.S./B.S. in Pharmacy, Chungnam National University
Ph.D. / Head of Medicinal Chemistry
Joonwoo Nam
  • CSO, Onconic Therapeutics Inc.
  • Director of Medicinal Chemistry, Jeil Pharmaceutical Co., Ltd.
  • Principal Research Scientist, CrystalGenomics Inc.
  • Research Scientist, CytRx Corporation
  • Post-doc. Fellow, The Scripps Research Institute
  • Ph.D. in Organic Chemistry, Princeton University
  • M.S./B.S. in Chemistry, Yonsei University
Ph.D. / Head of Biology
Wonil Kim
  • Staff Scientist, St. Jude Children's Research Hospital
  • Post-doc. Fellow, Frederick National Laboratory of Cancer Research
  • Post-doc. Research Fellow, Harvard Medical School
  • Supervisor of Deheny Eye Institute, U. of Southern California
  • Ph.D. in Molecular Biology & Genetics, U. of Minnesota
  • M.S./B.S. in Microbiology, Chungnam National University
Ph.D. / Head of Pharmacology
Eun-Jung Kim
  • Senior Research Fellow, Dong-A ST/Dong-A Socio Holdings
  • Ph.D. in Pharmacology, Seoul National University
  • B.S./M.S. in Pharmacy, Seoul National University
Executive Director / COO
Cheol-Jun Bae
  • Executive Director, Planning/BD, SCAI Therapeutics
  • Team Leader of Business Development, Dong-A ST
  • Team Leader of Research Planning, Dong-A Pharmaceutical
  • Sungkyunkwan Univ. Ph.D. course work for industrial pharmacy
  • M.S./B.S. in Pharmacy, Seoul National University
Executive Director / CFO
Yong Cheol Kang
  • General Manager, Investment Banking Division (IPO, M&A, Fundraising), Mirae Asset Daewoo
  • B.A. in Business Administration, Konkuk University